1.Founder Mutations for Early Onset Melanoma as Revealed by Whole Exome Sequencing Suggests That This is Not Associated with the Increasing Incidence of Melanoma in Poland.
Tadeusz DĘBNIAK ; Rodney J SCOTT ; Rodney A LEA ; Bohdan GÓRSKI ; Bartłomiej MASOJĆ ; Cezary CYBULSKI ; Andrzej KRAM ; Romuald MALESZKA ; Tomasz GROMOWSKI ; Katarzyna PASZKOWSKA-SZCZUR ; Aniruddh KASHYAP ; Marcin R LENER ; Karolina MALIŃSKA ; Emilia ROGOŻA ; Dawid MURAWA ; Helena RUDNICKA ; Jakub DEPTUŁA ; Jan LUBIŃSKI
Cancer Research and Treatment 2019;51(1):337-344
PURPOSE: Germline mutations within melanoma susceptibility genes are present only in minority of melanoma patients and it is expected that additional genes will be discovered with next generation sequence technology and whole-exome sequencing (WES). MATERIALS AND METHODS: Herein we performed WES on a cohort of 96 unrelated Polish patients with melanoma diagnosed under the age of 40 years who all screened negative for the presence of CDKN2A variants. A replication study using a set of 1,200 melanoma patient DNA samples and similarly large series of healthy controls was undertaken. RESULTS: We selected 21 potentially deleterious variants in 20 genes (VRK1, MYCT1, DNAH14, CASC3, MS4A12, PRC1, WWOX, CARD6, EXO5, CASC3, CASP8AP2, STK33, SAMD11, CNDP2, CPNE1, EFCAB6, CABLES1, LEKR1, NUDT17, and RRP15), which were identified by WES and confirmed by Sanger sequencing for an association study. Evaluation of the allele distribution among carriers and their relatives in available family trios revealed that these variants were unlikely to account for many familial cases of melanoma. Replication study revealed no statistically significant differences between cases and controls. CONCLUSION: Although most of the changes seemed to be neutral we could not exclude an association between variants in VRK1, CREB3L3, EXO5, and STK33 with melanoma risk.
Alleles
;
Cohort Studies
;
DNA
;
Exome*
;
Frameshift Mutation
;
Germ-Line Mutation
;
Humans
;
Incidence*
;
Melanoma*
;
Poland*
2.Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer.
Marcin R LENER ; Rodney J SCOTT ; Anna WIECHOWSKA-KOZŁOWSKA ; Pablo SERRANO-FERNÁNDEZ ; Piotr BASZUK ; Katarzyna JAWORSKA-BIENIEK ; Grzegorz SUKIENNICKI ; Wojciech MARCINIAK ; Magdalena MUSZYŃSKA ; Józef KŁADNY ; Tomasz GROMOWSKI ; Katarzyna KACZMAREK ; Anna JAKUBOWSKA ; Jan LUBIŃSKI
Cancer Research and Treatment 2016;48(3):1056-1064
PURPOSE: Understanding of the etiology and pathogenesis of pancreatic cancer (PaCa) is still insufficient. This study evaluated the associations between concentrations of selenium (Se) and copper (Cu) in the serum of PaCa patients. MATERIALS AND METHODS: The study included 100 PaCa patients and 100 control subjects from the same geographical region in Poland. To determine the average concentration of Se, Cu, and ratio Cu:Se in the Polish population, assay for Se and Cu was performed in 480 healthy individuals. Serum levels of Se and Cu were measured using inductively coupled plasma mass spectrometry. RESULTS: In the control group, the average Se level was 76 µg/L and Cu 1,098 µg/L. The average Se level among PaCa patients was 60 µg/L and the mean Cu level was 1,432 µg/L. The threshold point at which any decrease in Se concentration was associated with PaCa was 67.45 µg/L. The threshold point of Cu level above which there was an increase in the prevalence of PaCa was 1,214.58 µg/L. In addition, a positive relationship was observed between increasing survival time and Se plasma level. CONCLUSION: This retrospective study suggests that low levels of Se and high levels of Cu might influence development of PaCa and that higher levels of Se are associated with longer survival in patients with PaCa. The results suggest that determining the level of Se and Cu could be incorporated into a risk stratification scheme for the selection and surveillance control examination to complement existing screening and diagnostic procedures.
Complement System Proteins
;
Copper*
;
Humans
;
Mass Screening
;
Mass Spectrometry
;
Pancreatic Neoplasms*
;
Plasma
;
Poland
;
Prevalence
;
Retrospective Studies
;
Selenium*